← All drugs
Drug · FAERS side-effect profile with label screen

Oxycodone Hydrochloride side effects: what 215,964 FDA adverse event reports show

Oxycodone Hydrochloride · Oxycodone Hydrochloride · 1,232 reaction terms · 908,199 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Brand names

Oxycodone Hydrochloride

openFDA label

Who reports

215,964 reports · 90% serious · 52,889 with death outcome · 45% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdo.

FDA label, Indications and Usage

What it is

Oxycodone is a semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.

PubChem CID 5284603 (ChEBI)

Boxed warning

SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 2Labeled (related wording) 7Reporting / coding artifact 5Lab value / disease marker 5Not in label — unassessed 21
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,192 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Polysubstance abuse400160.7
136.8–188.7ROR 161.0 · calibrated p 3e-9 ✓
60.1 EB05 55.3 · IC025 +5.6
3/3 methods agree
Reporting / coding artifactserious n=399no trial arm names this drug
Drug dependence100,436158.4
157.0–159.9ROR 295.3 · calibrated p 1e-11 ✓
59.9 EB05 59.6 · IC025 +5.9
3/3 methods agree
Reporting / coding artifactage-adj. PRR 49.6 · serious PRR 38.9 · 94% consumerno trial arm names this drug
Learning disability3,067128.8
122.0–135.9ROR 130.6 · calibrated p 1e-8 ✓
55.2 EB05 53.5 · IC025 +5.7
3/3 methods agree
Not in label — unassessedserious n=3,059 · 100% consumerno trial arm names this drug
Neonatal hypoacusis126112.7
87.0–145.9ROR 112.8 · calibrated p 7e-8 ✓
51.7 EB05 44.5 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=126 · 100% consumerno trial arm names this drug
Vision abnormal neonatal222107.4
88.6–130.1ROR 107.5 · calibrated p 8e-8 ✓
50.7 EB05 45.3 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=222 · 100% consumerno trial arm names this drug
Presbyacusis14382.7
66.1–103.4ROR 82.7 · calibrated p 6e-7 ✓
44.4 EB05 38.6 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=143 · ♀ 100% (drug 45%)no trial arm names this drug
Drug withdrawal syndrome36,96469.3
68.4–70.2ROR 83.4 · calibrated p 4e-7 ✓
40.5 EB05 40.1 · IC025 +5.3
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 12.7 · serious PRR 31.9 · 83% consumerno trial arm names this drug
Emotional distress48,59764.6
63.9–65.3ROR 83.1 · calibrated p 4e-7 ✓
38.8 EB05 38.5 · IC025 +5.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 4.0 · serious PRR 27.3 · 93% consumerno trial arm names this drug
Drug abuser2,26255.2
52.4–58.1ROR 55.8 · calibrated p 7e-6 ✓
35.2 EB05 34.0 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=2,261no trial arm names this drug
Self esteem decreased80647.7
43.8–51.9ROR 47.9 · calibrated p 2e-5 ✓
32.0 EB05 30.2 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=805 · 100% consumerno trial arm names this drug
Drug diversion1,88747.5
45.0–50.2ROR 47.9 · calibrated p 2e-5 ✓
32.0 EB05 30.8 · IC025 +4.9
3/3 methods agree
Reporting / coding artifactserious n=905 · 96% consumerno trial arm names this drug
Drug withdrawal syndrome neonatal4,70944.4
42.9–46.0ROR 45.4 · calibrated p 2e-5 ✓
30.6 EB05 29.8 · IC025 +4.9
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 19.5 · 100% consumerno trial arm names this drug
Developmental delay2,71441.1
39.3–42.9ROR 41.6 · calibrated p 4e-5 ✓
29.0 EB05 28.0 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious PRR 18.6 · 100% consumerno trial arm names this drug
Victim of homicide16038.1
31.7–45.8ROR 38.1 · calibrated p 8e-5 ✓
27.4 EB05 24.0 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=160 · 100% consumerno trial arm names this drug
Imprisonment44331.7
28.4–35.3ROR 31.7 · calibrated p 2e-4 ✓
24.0 EB05 22.2 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=443 · ♀ 21% (drug 45%) · 100% consumerno trial arm names this drug
Anti-cyclic citrullinated peptide antibody15228.4
23.7–34.1ROR 28.4 · calibrated p 4e-4 ✓
22.0 EB05 19.3 · IC025 +4.1
3/3 methods agree
Lab value / disease markerserious n=152 · ♀ 100% (drug 45%) · 100% clinicianno trial arm names this drug
Overdose49,03228.2
28.0–28.5ROR 36.2 · calibrated p 9e-5 ✓
22.0 EB05 21.8 · IC025 +4.4
3/3 methods agree
Reporting / coding artifactage-adj. PRR 8.7 · serious PRR 17.6 · 89% consumerno trial arm names this drug
Deep vein thrombosis postoperative43627.6
24.8–30.7ROR 27.6 · calibrated p 4e-4 ✓
21.6 EB05 19.9 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=436 · ♀ 100% (drug 45%)no trial arm names this drug
Delusional disorder, unspecified type16326.9
22.6–32.0ROR 26.9 · calibrated p 5e-4 ✓
21.1 EB05 18.5 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=163 · 100% clinicianno trial arm names this drug
Lupus vulgaris25726.5
23.1–30.5ROR 26.6 · calibrated p 5e-4 ✓
20.9 EB05 18.9 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=257 · ♀ 100% (drug 45%) · 100% clinicianno trial arm names this drug
Adjustment disorder with depressed mood42826.0
23.3–28.9ROR 26.0 · calibrated p 6e-4 ✓
20.6 EB05 19.0 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=426 · ♀ 100% (drug 45%) · 100% clinicianno trial arm names this drug
Detoxification7325.5
19.7–33.1ROR 25.5 · calibrated p 7e-4 ✓
20.2 EB05 16.6 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=70 · ♀ 0% (drug 45%) · 100% consumerno trial arm names this drug
C-reactive protein18624.8
21.1–29.2ROR 24.9 · calibrated p 7e-4 ✓
19.9 EB05 17.6 · IC025 +4.0
3/3 methods agree
Lab value / disease markerserious n=186 · ♀ 100% (drug 45%) · 100% clinicianno trial arm names this drug
Swollen joint count increased60623.2
21.3–25.4ROR 23.3 · calibrated p 1e-3 ✓
18.8 EB05 17.6 · IC025 +4.1
3/3 methods agree
Lab value / disease markerserious n=606 · ♀ 100% (drug 45%) · 100% clinicianno trial arm names this drug
X-ray abnormal33822.5
20.0–25.3ROR 22.5 · calibrated p 0.001 ✓
18.4 EB05 16.8 · IC025 +4.0
3/3 methods agree
Lab value / disease markerserious n=338 · ♀ 100% (drug 45%) · 100% clinicianno trial arm names this drug
Duodenal ulcer perforation1,37322.2
20.9–23.5ROR 22.3 · calibrated p 0.001 ✓
18.1 EB05 17.4 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious PRR 11.5 · ♀ 100% (drug 45%)no trial arm names this drug
Facet joint syndrome56621.1
19.2–23.1ROR 21.1 · calibrated p 0.002 ✓
17.4 EB05 16.2 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=566 · ♀ 100% (drug 45%)no trial arm names this drug
Anti-cyclic citrullinated peptide antibody positive1,27121.0
19.7–22.3ROR 21.1 · calibrated p 0.002 ✓
17.4 EB05 16.6 · IC025 +4.0
3/3 methods agree
Lab value / disease markerserious PRR 11.1 · ♀ 100% (drug 45%)no trial arm names this drug
Pleural fibrosis18020.4
17.4–23.9ROR 20.4 · calibrated p 0.002 ✓
16.9 EB05 14.9 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=180 · ♀ 100% (drug 45%)no trial arm names this drug
Rheumatic fever76020.3
18.8–21.9ROR 20.4 · calibrated p 0.002 ✓
16.9 EB05 15.9 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=760 · ♀ 100% (drug 45%) · 94% clinicianno trial arm names this drug
Substance abuse1,41220.2
19.0–21.4ROR 20.3 · calibrated p 0.002 ✓
16.8 EB05 16.1 · IC025 +4.0
3/3 methods agree
Reporting / coding artifactserious PRR 11.8 · 80% consumerno trial arm names this drug
Dislocation of vertebra38520.2
18.1–22.5ROR 20.2 · calibrated p 0.002 ✓
16.8 EB05 15.4 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=385 · ♀ 100% (drug 45%) · 92% clinicianno trial arm names this drug
Pleural thickening11720.0
16.3–24.4ROR 20.0 · calibrated p 0.002 ✓
16.6 EB05 14.2 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=117 · ♀ 100% (drug 45%) · 100% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Dependence / withdrawal105,01953.353.0–53.6signal
Depression8,5413.02.9–3.1signal
Suicidality5,8872.42.3–2.4signal
Interstitial lung disease1,4831.51.4–1.6raised
Liver injury4,0371.31.3–1.3raised
Serious infection8,0591.01.0–1.0no difference
Osteonecrosis5991.00.9–1.1no difference
Fall / fracture3,6650.90.9–1.0lower than other drugs
Venous thromboembolism1,9540.90.8–0.9lower than other drugs
Rhabdomyolysis / myopathy7030.80.8–0.9lower than other drugs
Kidney injury3,8750.80.8–0.8lower than other drugs
Hyponatraemia6580.80.7–0.9lower than other drugs
Thrombocytopenia1,7810.80.7–0.8lower than other drugs
Anaemia2,3110.70.7–0.8lower than other drugs
Seizure1,4550.70.7–0.8lower than other drugs
Myocardial infarction1,4810.70.7–0.7lower than other drugs

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Oxycodone Hydrochloride only as a background or rescue medication (NCT02625181, NCT04296396); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug dependence100,436158.4
157.0–159.9ROR 295.3 · calibrated p 1e-11 ✓
59.9 EB05 59.6 · IC025 +5.9
3/3 methods agree
Reporting / coding artifactage-adj. PRR 49.6 · serious PRR 38.9 · 94% consumerno trial arm names this drug
Pain56,2519.7
9.6–9.8ROR 12.7 · calibrated p 0.013 ✓
8.9 EB05 8.8 · IC025 +3.1
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 3.0 · serious PRR 8.6no trial arm names this drug
Overdose49,03228.2
28.0–28.5ROR 36.2 · calibrated p 9e-5 ✓
22.0 EB05 21.8 · IC025 +4.4
3/3 methods agree
Reporting / coding artifactage-adj. PRR 8.7 · serious PRR 17.6 · 89% consumerno trial arm names this drug
Emotional distress48,59764.6
63.9–65.3ROR 83.1 · calibrated p 4e-7 ✓
38.8 EB05 38.5 · IC025 +5.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 4.0 · serious PRR 27.3 · 93% consumerno trial arm names this drug
Drug withdrawal syndrome36,96469.3
68.4–70.2ROR 83.4 · calibrated p 4e-7 ✓
40.5 EB05 40.1 · IC025 +5.3
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 12.7 · serious PRR 31.9 · 83% consumerno trial arm names this drug
Death23,8302.7
2.7–2.8ROR 3.0 · calibrated p 0.643
2.7 EB05 2.7 · IC025 +1.4
3/3 methods agree
Outcome field, not a reaction
boxed warning mentions mortality
age-adj. PRR 1.5 · serious PRR 1.7 · 75% consumerno trial arm names this drug
Toxicity to various agents14,0308.8
8.6–8.9ROR 9.3 · calibrated p 0.041 ✓
8.1 EB05 8.0 · IC025 +3.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 5.2 · serious PRR 5.3no trial arm names this drug
Drug abuse8,07310.3
10.0–10.5ROR 10.6 · calibrated p 0.026 ✓
9.4 EB05 9.2 · IC025 +3.2
3/3 methods agree
Reporting / coding artifactage-adj. PRR 7.8 · serious PRR 6.0 · 75% consumerno trial arm names this drug
Anxiety8,0292.8
2.7–2.8ROR 2.9 · calibrated p 0.676
2.7 EB05 2.7 · IC025 +1.4
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.4 · serious PRR 2.3no trial arm names this drug
Depression7,9223.5
3.4–3.5ROR 3.5 · calibrated p 0.474
3.4 EB05 3.3 · IC025 +1.7
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 3.3 · serious PRR 2.9no trial arm names this drug
Nausea7,8171.0
0.9–1.0ROR 1.0 · calibrated p 0.281
1.0 EB05 0.9 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 0.9no trial arm names this drug
Drug ineffective (drug did not work)6,9670.5
0.5–0.5ROR 0.5 · calibrated p 0.047 ✓
0.5 EB05 0.5 · IC025 -1.0
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 1.2 · serious PRR 0.6no trial arm names this drug
Fatigue (tiredness)6,6710.8
0.8–0.9ROR 0.8 · calibrated p 0.199
0.8 EB05 0.8 · IC025 -0.3
PRR-only: not supported by EBGM or IC
Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 0.8 · ♀ 66% (drug 45%)no trial arm names this drug
Vomiting5,8291.2
1.2–1.2ROR 1.2 · calibrated p 0.451
1.2 EB05 1.2 · IC025 +0.2Labeled adverse reaction
exact term
age-adj. PRR 2.3 · serious PRR 1.0no trial arm names this drug
Diarrhoea (diarrhea)5,1800.8
0.8–0.8ROR 0.8 · calibrated p 0.170
0.8 EB05 0.8 · IC025 -0.4
PRR-only: not supported by EBGM or IC
Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 0.7no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone ↔ Drug dependence / withdrawal syndrome.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Oxycodone Hydrochloride?

In FDA FAERS, the most frequently co-reported reaction terms for Oxycodone Hydrochloride are pain, emotional distress, drug withdrawal syndrome, toxicity to various agents, anxiety, depression. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Oxycodone Hydrochloride have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.

Do FAERS signals prove that Oxycodone Hydrochloride causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.